Top House Dem Buys Stock in Pharma Companies and Defense Contractors
House Budget Chair John Yarmuth is a frequent stock trader who recently purchased shares in companies that are lobbying against the Democrats' budget plan.
House Democrats
Page 3
Ascending Dem Hawk Wants to Pre-Authorize War With China
In a Washington Post op-ed, Rep. Elaine Luria (D-Va.) said Congress should preemptively authorize military action to defend Taiwan against China.
Top Democrats Own Stock in AT&T, Funder of Far-Right OAN Network
A recent investigation revealed that 90% of the far-right network OAN's funding comes from AT&T-owned platforms.
Deficit Fears Have Deep History in Corporate-Funded Democratic Party Groups
As corporate-backed Democrats threaten to block the party's reconciliation bill, their talking points draw on support from deficit scold allies among party leaders and well-funded ideological groups.
Corporate PACs Reward Democrats Opposing Reconciliation Package
Nine Democrats threatening to sink the reconciliation bill pulled in more than $150,000 in PAC donations last month.
House to Vote on the Largest Defense Budget in History
House progressives have again introduced amendments to significantly reduce the massive Pentagon budget of at least $768 billion.
Neal’s Reconciliation Plan Lets Investment Managers Keep Their Tax Loophole
Richard Neal supported closing the carried interest loophole in 2007, then began receiving more donations from the securities and investment industry.
It’s Not Just Manchin: The Top Energy Dem in the House Also Has Fossil Fuel Conflicts
Rep. Frank Pallone (D-N.J.), chair of the House Energy and Commerce Committee, benefits from investments in the fossil fuel industry while crafting climate policies.
Corporate-Backed Blue Dogs Threaten Democrats’ Budget Plan
Facing health care and climate crises, a group of six conservative House Democrats are seeking to pump the brakes on the largest federal investments in decades.
Pharma Companies Spend Billions More on Stock Buybacks Than Developing Drugs, House Report Finds
The largest drugmakers spent $56 billion more on stock buybacks and dividends than on research and development from 2016 to 2020, according to a new House committee report.